Sutro Biopharma, Inc.: dividend

STRONASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$9.82

November 13, 2026Market cap $163M

DCF calculator

What Ploutos Investor adds for Sutro Biopharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Sutro Biopharma pays no dividend

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 1.4% in a year.

All dividend stocks

The full analysis

What do Sutro Biopharma's filings show?

The dividend is one part of Sutro Biopharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about STRO's dividend

Didn't find what you were looking for?

Ask us
Does STRO pay a dividend?

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 1.4% in a year.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.GlossaryEvery figure in plain words: what it is, how it is worked out, how to read it.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.